http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H10512277-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33b011e77b33662b8bf1f2ff2de7b661 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B05B7-066 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6897 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7036 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7028 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-232 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B05B7-06 |
| filingDate | 1996-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1998-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H10512277-A |
| titleOfInvention | Compounds for preventing multidrug resistance in cancer cells containing protein kinase inhibitors |
| abstract | (57) [Summary]nThe present invention is directed to a method of preventing the emergence of multidrug resistance in cancer cells during cancer chemotherapy. In particular, the present invention relates to the use of protein kinase inhibitors to prevent the induction of expression of the multidrug resistance (MDR1) gene encoding P-glycoprotein by chemotherapeutic drugs, including the use of certain chemotherapeutic drugs. MDR1 expression, which results in tumor cell resistance to subsequent treatment of, is associated with a variety of cytotoxic agents, including agents that are substrates for P-glycoprotein-mediated efflux from cancer cells and those that are not. It is shown here that it is induced in response to treatment. It is now shown that inhibitors of protein kinases, especially protein kinase C, suppress this cellular response. It is further shown herein that such protein kinase inhibitors inhibit the expression of the gene encoding the multidrug resistance-related protein (MRP gene). The present invention provides a method of using a protein kinase inhibitor for both inhibiting the inhibition of MDR1 gene expression by a cytotoxic drug and inhibiting MRP expression. The present invention also provides methods for identifying protein kinase inhibitors that have either or both of these effects on MDR1 and MRP expression. Thus, the present invention provides a method for treating cytotoxic drugs and chemotherapy in cancer patients receiving chemotherapy when administering a protein kinase inhibitor prior to or concurrent with cytotoxic drug treatment in patients receiving chemotherapy. It is intended to provide useful methods and reagents for preventing the emergence of multidrug resistance in drug-treated tumor cells. |
| priorityDate | 1995-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 146.